DANYELZA, also known as Hu3F8 or naxitamab, may help your child
Get study resultsDANYELZA is the ONLY FDA-approved immunotherapy for high-risk neuroblastoma that:
- Is specifically for children who had an incomplete response to induction or relapse therapy and who also have disease in the bone and/or bone marrow
- Is HUMANIZED, or more closely resembles antibodies found in the human body
- Has the flexibility to be administered in either an INPATIENT or OUTPATIENT hospital setting, based on what your child’s doctor decides
DANYELZA is used in combination with another medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF).